Sutro Biopharma, Inc (STRO)

Etorro trading 970x250
Sutro Biopharma, Inc (STRO) Logo

About Sutro Biopharma, Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Address: 310 Utah Avenue, South San Francisco, CA, United States, 94080

Sutro Biopharma, Inc News and around…

Latest news about Sutro Biopharma, Inc (STRO) common stock and company :

Sutro Biopharma to Participate in Two Upcoming Investor Conferences
22 Nov, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two upcoming virtual investor conferences.

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
17 Nov, 2021 FinancialContent

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. ...

Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
17 Nov, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Heidi Hunter has been appointed to Sutro's Board of Directors.

Add Up The Pieces: ESML Could Be Worth $48
15 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.44 per unit.

Sutro Biopharma Earnings Perspective: Return On Capital Employed
11 Nov, 2021 FinancialContent

Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q3 sales of $8.52 million. Earnings fell to a loss of $34.67 million, ...

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
10 Nov, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended September 30, 2021, its recent business highlights, and a preview of anticipated select milestones in the remainder of 2021.

Sutro Biopharma to Participate in Three Upcoming Investor Conferences
02 Nov, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in three upcoming virtual investor conferences.

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
28 Oct, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should I Avoid Sutro Biopharma, Inc. (STRO)?
19 Oct, 2021 Yahoo! Finance

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
16 Oct, 2021 FinancialContent

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones.

Sutro Biopharma, BioNova Pharmaceuticals Join Hands in Greater China
13 Oct, 2021 Yahoo! Finance

Clinical-stage drug discovery, development and manufacturing company Sutro Biopharma, Inc. (STRO) recently announced that it has entered into an option agreement with BioNova Pharmaceuticals Limited to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate (ADC), for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Following the news, shares of the company appreciated 3.3% to close at $19.22 on Tuesday. Under this a

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
12 Oct, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, and BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today jointly announced an option agreement for BioN

Merck, Sutro Biopharma Extends Cytokine Derivative Research Program
30 Sep, 2021 FinancialContent

Merck & Co Inc(NYSE: MRK) hasextended the research term by two yearsfor the first cytokine derivative program ...

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
30 Sep, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as MSD outside the United States and Canada, has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years. The research extension is intended to

Chief Port. Strat And Alnce Ofcr Of Sutro Biopharma Trades $112 Thousand In Company Stock
29 Sep, 2021 Yahoo! Finance

Nicki Vasquez, Chief Port. Strat And Alnce Ofcr at Sutro Biopharma (NASDAQ:STRO), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Nicki Vasquez exercised options to purchase 5,969 Sutro Biopharma shares for $0 on September 28. They then sold their shares on multiple transactions in the open market. They sold at prices ranging from $18.62 to $19.23 to raise a tot

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Sep, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that on September 15, 2021, the Compensation Committee of Sutro's Board of Directors granted restricted stock unit awards (RSUs) representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggrega

Sutro Biopharma Announces Expansion of Leadership Team
16 Sep, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced today the appointment of two executives to the Company's leadership team. Nicole M. Chieffo, MBA, has joined as Vice President of Clinical Operations and Werner Rubas, Ph.D., has joined as Vice President of Preclinical Development.

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
01 Sep, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell, Chief Executive Officer, will participate in the 2021 Wells Fargo Securities Healthcare Conference during a virtual fireside chat on Thursday, September 9, at 3:20 p.m. ET / 12:20 p.m. PT.

Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
19 Aug, 2021 Yahoo! Finance

Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
19 Aug, 2021 Yahoo! Finance

Shareholders in Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be thrilled to learn that the analysts have just delivered a...

Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US
18 Aug, 2021 FinancialContent

TheFDA has granted Fast Track designationtoSutro Biopharma Inc's(NASDAQ: STRO) STRO-002 for ovarian ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
18 Aug, 2021 Yahoo! Finance

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant epithelial

Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
11 Aug, 2021 Yahoo! Finance

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

EES's Holdings Imply 13% Gain Potential
16 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree US.

First Week of STRO February 2022 Options Trading
21 Jun, 2021 FinancialContent

Investors in Sutro Biopharma Inc (STRO) saw new options begin trading this week, for the February 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

STRO Makes Bullish Cross Above Critical Moving Average
18 Jun, 2021 FinancialContent

In trading on Friday, shares of Sutro Biopharma Inc (STRO) crossed above their 200 day moving average of $19.01, changing hands as high as $20.32 per share. Sutro Biopharma Inc shares are currently trading up about 5.6% on the day..

Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021
18 Jun, 2021 FinancialContent

Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE:OEC) was changed from Neutral to ...

The Implied Analyst 12-Month Target For LABU
10 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.20 per unit.

Sutro Biopharma, Inc (STRO) is a NASDAQ Common Stock listed in , ,

970x250